This is the first trial in the clinical development of IBP-9414 for the prevention of the often fatal disease necrotizing enterocolitis which affects premature infants. The multicenter trial is being conducted in a number of neonatal intensive care units in the US and will enroll 120 premature infants.
More information about the clinical trial can be found on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02472769).
Staffan Strömberg, Chief Executive Officer of IBT, comments, "We are very excited to have started the study and to now have the first baby included. This is an important milestone in our development of this potentially life-saving new drug."
For additional information please contact
Staffan Strömberg, CEO, phone: +46 8 410 145 55
Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55
Infant Bacterial Therapeutics AB
111 21 Stockholm, Sweden
Phone: +46 8 410 145 55